JP2022539952A - 結腸・直腸がんを治療するための薬物の製造におけるfgf21の使用 - Google Patents
結腸・直腸がんを治療するための薬物の製造におけるfgf21の使用 Download PDFInfo
- Publication number
- JP2022539952A JP2022539952A JP2021570517A JP2021570517A JP2022539952A JP 2022539952 A JP2022539952 A JP 2022539952A JP 2021570517 A JP2021570517 A JP 2021570517A JP 2021570517 A JP2021570517 A JP 2021570517A JP 2022539952 A JP2022539952 A JP 2022539952A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- fgf21
- protein
- fgf21 protein
- colorectal cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title claims abstract description 50
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title claims abstract description 50
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 37
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 230000004060 metabolic process Effects 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 230000004153 glucose metabolism Effects 0.000 claims description 6
- 102000009127 Glutaminase Human genes 0.000 claims description 5
- 108010073324 Glutaminase Proteins 0.000 claims description 5
- 102100029242 Hexokinase-2 Human genes 0.000 claims description 5
- 101710198385 Hexokinase-2 Proteins 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 4
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 4
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 4
- 101100120063 Homo sapiens FGF21 gene Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 101710088194 Dehydrogenase Proteins 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 108010069341 Phosphofructokinases Proteins 0.000 claims description 2
- 102000001105 Phosphofructokinases Human genes 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 claims description 2
- 108020005115 Pyruvate Kinase Proteins 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003596 drug target Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 9
- 206010027476 Metastases Diseases 0.000 abstract description 6
- 150000001413 amino acids Chemical class 0.000 abstract description 6
- 230000009401 metastasis Effects 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 2
- 230000009545 invasion Effects 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- 238000010172 mouse model Methods 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 102000040739 Secretory proteins Human genes 0.000 abstract 1
- 108091058545 Secretory proteins Proteins 0.000 abstract 1
- 230000002380 cytological effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 229910001868 water Inorganic materials 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- DGAKHGXRMXWHBX-ONEGZZNKSA-N Azoxymethane Chemical compound C\N=[N+](/C)[O-] DGAKHGXRMXWHBX-ONEGZZNKSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 229920003045 dextran sodium sulfate Polymers 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- 102100025514 ATP-dependent 6-phosphofructokinase, platelet type Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000693765 Homo sapiens ATP-dependent 6-phosphofructokinase, platelet type Proteins 0.000 description 2
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 102000056713 human FGF21 Human genes 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011470 radical surgery Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101150068639 Hnf4a gene Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011498 curative surgery Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
FGF21タンパク質は、微生物細胞を培養することにより製造され、製造方法は、登録番号CN106432509 Bの特許出願に開示されている。
実施例1の方法に応じてアミノ酸配列が例えば、SEQ ID NO.1に示されるFGF21タンパク質を製造した。
実施例1の方法に応じてアミノ酸配列が例えば、SEQ ID NO.1に示されるFGF21タンパク質を製造した。
実施例1の方法に応じてアミノ酸配列が例えば、SEQ ID NO.1に示されるFGF21タンパク質を製造した。
(1)10%(w/v)のラウリル硫酸ナトリウムSDS溶液:0.1gのSDS、及び1ミリリットルのH2O脱イオン水で調製し、室温で保存した。
BCA法によるタンパク質の濃度の測定:0.5mg/mLの標準タンパク質のラダーをウェルプレートに加え、PBSで20μLまで補充し、適切な体積(3μL)のタンパク質サンプルをウェルプレートに加え、PBSで20μLまで補充し、各ウェルに200μLのBCA作動液を添加し(使用前に調製して使用に備える)、37℃で30分間、インキュベートし、波長562nmでの吸光度を測定し、標準曲線及びサンプル体積によりタンパク質の濃度を算出した。
(1)洗浄されたガラス板を整列させた後にクランプに入れて係止し、次にラックに垂直に係止されてゲルを注入した。
(1)ゲル切断:ガラス板を除去し、小さいガラス板を除去した後、濃縮ゲルを掻き取り、実験の需要に基づいてタンパク質の分子量に応じて、Markerを対照としてゲルを切断した。
(1)密閉:メンブレンをTBSTで3回洗浄(各回5分間)を行った。洗浄後にニトロセルロース膜を5%の脱脂粉乳に入れ、室温でシェーカーで1時間、インキュベートした。
(1)A及びBの2種類の試薬を、小遠心分離管に、発光キットのプロトコールに応じて操作してそれを混合し、ニトロセルロース膜に加え、化学発光イメージャーで発色させた。
Claims (12)
- 結腸・直腸がんを予防、緩和及び/又は治療する薬物の製造におけるFGF21タンパク質の使用であって、前記FGF21タンパク質のアミノ酸配列は、SEQ ID NO.1~5又はSEQ ID NO.11~14のいずれかに示される、使用。
- 前記FGF21タンパク質の有効用量が0.1~10mg/kgである、請求項1に記載の使用。
- 結腸・直腸がんを治療する薬物であって、FGF21タンパク質を有効成分として、前記FGF21タンパク質のアミノ酸配列がSEQ ID NO.1~5又はSEQ ID NO.11~14のいずれかに示される、薬物。
- さらに、薬学的に許容可能な担体又は補助材を含む、請求項3に記載の薬物。
- 前記薬物の投与経路は、経口投与、腹腔内注射、皮下注射、静脈内注射又は筋肉注射を含む、請求項4に記載の薬物。
- 結腸・直腸がんを治療する薬物のスクリーニングにおける薬物標的としての、FGF21遺伝子の使用。
- FGF21タンパク質の小分子活性化剤をスクリーニングする、請求項6に記載の使用。
- 腫瘍糖代謝及び/又はグルタミン代謝阻害剤の製造における、FGF21タンパク質の使用。
- ヘキソキナーゼ2、ピルビン酸キナーゼ、ホスホフルクトキナーゼ、ピルビン酸デヒドロゲナーゼ酵素、グルコース-6-リン酸デヒドロゲナーゼのうちの1種又は複数種である腫瘍糖代謝の重要なタンパク質を阻害する阻害剤を製造する、請求項8に記載の使用。
- グルタミナーゼの阻害剤を製造する、請求項8に記載の使用。
- がんを予防、緩和及び/又は治療する薬物の製造における、FGF21タンパク質の使用。
- 前立腺がん、乳がん、食道がん、結腸・直腸がん、子宮頸がん、子宮内膜がん、卵巣がん、膵臓がん、胆嚢がん、肝臓がん、淡明細胞型腎がん、黒色腫、多発性骨髄腫のうちの1種又は複数種の疾患を予防、緩和及び/又は治療する薬物の製造における使用である、請求項11に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010396043.1 | 2020-05-12 | ||
CN202010396043.1A CN111420030B (zh) | 2020-05-12 | 2020-05-12 | Fgf21在制备用于治疗结直肠癌药物中的应用 |
PCT/CN2020/136762 WO2021227493A1 (zh) | 2020-05-12 | 2020-12-16 | Fgf21在制备用于治疗结直肠癌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022539952A true JP2022539952A (ja) | 2022-09-14 |
JP7302025B2 JP7302025B2 (ja) | 2023-07-03 |
Family
ID=71550884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021570517A Active JP7302025B2 (ja) | 2020-05-12 | 2020-12-16 | 結腸・直腸がんを治療するための薬物の製造におけるfgf21の使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220111007A1 (ja) |
EP (1) | EP4008338A4 (ja) |
JP (1) | JP7302025B2 (ja) |
CN (1) | CN111420030B (ja) |
WO (1) | WO2021227493A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111420030B (zh) * | 2020-05-12 | 2021-01-29 | 江南大学 | Fgf21在制备用于治疗结直肠癌药物中的应用 |
CN112851791B (zh) * | 2021-03-12 | 2021-10-22 | 江南大学 | 一种新型抗代谢紊乱的fgf类似物及其应用 |
CN113912699A (zh) * | 2021-10-14 | 2022-01-11 | 江南大学 | 一种新型治疗乳腺癌的fgf类似物及其应用 |
CN113956344A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种新型治疗肝癌的fgf类似物及其应用 |
CN114316018A (zh) * | 2021-11-26 | 2022-04-12 | 江南大学 | 一种fgf21蛋白类似物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010139741A1 (en) * | 2009-06-04 | 2010-12-09 | Novartis Ag | Fgf-21 for treating cancers |
JP2016513073A (ja) * | 2012-12-27 | 2016-05-12 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 胆汁酸ホメオスタシス調整並びに胆汁酸障害及び疾患の治療の方法 |
CN106432509A (zh) * | 2016-09-13 | 2017-02-22 | 河南师范大学 | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008262450A1 (en) * | 2007-05-22 | 2008-12-18 | Novartis Ag | Methods of treating, diagnosing and detecting FGF21-associated disorders |
UA123763C2 (uk) * | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19 |
CN106220724B (zh) * | 2016-09-13 | 2019-10-11 | 河南师范大学 | 人成纤维细胞生长因子21重组蛋白及其制备方法和应用 |
JP7316946B2 (ja) * | 2017-07-06 | 2023-07-28 | イエール ユニバーシティ | 内分泌型fgf関連疾患を処置または防止するための組成物および方法 |
CN111420030B (zh) * | 2020-05-12 | 2021-01-29 | 江南大学 | Fgf21在制备用于治疗结直肠癌药物中的应用 |
-
2020
- 2020-05-12 CN CN202010396043.1A patent/CN111420030B/zh active Active
- 2020-12-16 EP EP20934983.6A patent/EP4008338A4/en active Pending
- 2020-12-16 JP JP2021570517A patent/JP7302025B2/ja active Active
- 2020-12-16 WO PCT/CN2020/136762 patent/WO2021227493A1/zh unknown
-
2021
- 2021-12-22 US US17/559,050 patent/US20220111007A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010139741A1 (en) * | 2009-06-04 | 2010-12-09 | Novartis Ag | Fgf-21 for treating cancers |
JP2016513073A (ja) * | 2012-12-27 | 2016-05-12 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 胆汁酸ホメオスタシス調整並びに胆汁酸障害及び疾患の治療の方法 |
CN106432509A (zh) * | 2016-09-13 | 2017-02-22 | 河南师范大学 | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
CANCERS, vol. 11, no. 8, JPN6023001575, 2019, pages 1154, ISSN: 0004971835 * |
GASTROENTEROLOGY, vol. 157, no. 5, JPN6023001574, 2019, pages 1413 - 1428, ISSN: 0004971834 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021227493A1 (zh) | 2021-11-18 |
JP7302025B2 (ja) | 2023-07-03 |
EP4008338A4 (en) | 2022-10-12 |
EP4008338A1 (en) | 2022-06-08 |
US20220111007A1 (en) | 2022-04-14 |
CN111420030B (zh) | 2021-01-29 |
CN111420030A (zh) | 2020-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7302025B2 (ja) | 結腸・直腸がんを治療するための薬物の製造におけるfgf21の使用 | |
US11318172B2 (en) | Use of genetically engineered bacterium of attenuated Salmonella typhimurium in for treating liver cancer | |
WO2021027045A1 (zh) | 一种基于激活jwa基因和降解her2的抗肿瘤化合物、其制备方法及其用途 | |
CN109675035A (zh) | LIN28/let-7信号通路抑制剂在制备调控PD-L1表达的药物中的应用 | |
JP2020509093A (ja) | 遺伝子工学菌vnp20009−mの肺癌予防・治療薬の製造における応用 | |
CN110201172A (zh) | Yy1表达抑制剂在制备治疗乳腺癌药物中的应用 | |
WO2017211317A1 (zh) | 一种多肽及其在制备治疗和/或预防肿瘤的药物中的应用 | |
CN108314676B (zh) | 含异羟肟酸片段的氨基吡啶类衍生物及其抗肿瘤应用 | |
CN113583095B (zh) | 抗肿瘤多肽及其用途 | |
CN113461675B (zh) | 一种针对skp2的小分子抑制剂tak-491及其应用 | |
CN113956344A (zh) | 一种新型治疗肝癌的fgf类似物及其应用 | |
WO2021243797A1 (zh) | 一种果蝇Hsp22蛋白在制备用于抗肿瘤的药物中的应用 | |
CN111686111B (zh) | Malt1蛋白酶抑制剂在制备非小细胞肺癌治疗药物中的应用 | |
CN106265619A (zh) | Dfmo或dfmo和姜提取物在制备食管癌和肝癌的预防及临床治疗的药物中的应用 | |
CN106222155A (zh) | 一种多肽及其在制备结肠炎及结肠炎相关结直肠癌药物中的应用 | |
CN112957357B (zh) | 一种靶向klf4泛素化的小分子抑制剂及其应用 | |
CN106928325B (zh) | 增强肝癌细胞对cik细胞杀伤敏感性的人工多肽及其生物制品 | |
CN113980963B (zh) | 一种寡核苷酸rna双链分子及其在制备治疗恶性肿瘤药物中的应用 | |
Tang et al. | Jin-Fu-An decoction manipulation of macrophage polarization via β-catenin (CTNNB1) synergizes with cisplatin in lung cancer | |
CN113754593B (zh) | 一种brd4蛋白抑制剂及其应用 | |
CN111848747B (zh) | 预防和/或治疗恶性肿瘤的多肽、应用及药物 | |
JP2019502742A (ja) | 腫瘍を予防・治療する医薬およびその用途 | |
CN106381297A (zh) | 抑制SOX2基因表达的双链p‑siRNA分子和p‑siRNA重组质粒及其应用 | |
CN101100679A (zh) | 一种表达抑制细胞生长多肽的腺病毒的构建及其应用 | |
CN113980963A (zh) | 一种寡核苷酸rna双链分子及其在制备治疗恶性肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230421 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230621 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7302025 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |